Interferon Apha 2b for Treating Patients with JAK2V617F Positive Polycythemia Vera and Essential Thrombocytosis

Abstract

<br/><b>Objective</b>: To investigate interferon (IFN) alpha 2 b for treating patients with JAK2V617F positivepolycythemia vera (PV) and essential thrombocytosis (ET). <br/><b>Methods</b>: Interferon alpha 2 b was used to treatpatients with JAK2V617F positive PV and ET. In control group, hydroxyurea was used. Endpoint of study wasto compare rates of hematological and molecular remission. <br/><b>Results</b>: Patients in the interferon alpha 2 b groupachieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, witha lower incidence of thrombosis. <br/><b>Conclusion</b>: Compared with hydroxyurea, interferon alpha 2 b could reduceJAK2V617F load for patients with PV and ET, and achieve higher molecular remission, improve treatmentefficacy and reduce complications.